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Cirrhosis commonly complicates portal hypertension worldwide but in Zambia hepatosplenic schistosomiasis
(HSS) dominates as the cause of portal hypertension. We need easier and non-invasive ways to assess HSS.
Transient elastography (TE), a measure of liver stiffness can diagnose liver cirrhosis. TE remains unexplored in
HSS patients, who generally have normal liver parenchyma. We aimed to explore liver stiffness in HSS. This
nested case control study was conducted at the University Teaching Hospital, Lusaka, Zambia between January
2015 and January 2016. We enrolled 48 adults with HSS and 22 healthy controls. We assessed liver stiffness using
TE while plasma hyaluronan was used to assess liver fibrosis. Plasma tumor necrosis factor receptor 1 (TNFR1)
and soluble cluster of differentiation 14 (sCD14) were used to assess inflammation. The median (interquartile
range) liver stiffness was higher in patients, 9.5 kPa (7.8, 12.8) than in controls, 4.7 kPa (4.0, 5.4), P < 0.0001. We
noted linear correlations of hyaluronan and TNFR1 with the liver stiffness, P ¼ 0.0307 and P ¼ 0.0003
respectively.
HSS patients seem to have higher liver stiffness than healthy controls. TE may be useful in identifying fibrosis in
HSS. The positive correlations of inflammatory markers with TE suggest that HSS has both periportal and
parenchymal pathophysiology.1. Introduction
Hepatosplenic schistosomiasis (HSS) in the tropics is an important
cause of portal hypertension and contributes significantly to mortality
and morbidity (Berhe et al., 2007; Kibiki et al., 2004; Sinkala et al.,
2016). Schistosomiasis is one of the neglected tropical diseases (Watts,
2017). Although cirrhosis is the leading cause of portal hypertension
worldwide, in Zambia a large proportion of cases are non-cirrhotic and
are due to schistosomiasis (Sinkala et al., 2016). Schistosomiasis is
endemic in some districts of Zambia and sero-prevalence is as high as
88% (Chipeta et al., 2009; Payne et al., 2013; Mutengo et al., 2014).
To diagnose liver fibrosis, liver biopsy is required as the gold stan-
dard, but this is invasive and is associated with some risk of bleeding andkala).
20 August 2019; Accepted 20 Ju
is an open access article under tsampling error (Ahmed et al., 2009; Seeff et al., 2010). Many authorities
are now advocating for non-invasive means of diagnosing liver fibrosis
(Marinho et al., 2010; Lombardi et al., 2015). Transient elastography
(TE, FibroScan®) is promising to be a non-invasive tool for assessing liver
fibrosis. Its clinical use in patients with liver disease is increasing and has
proved to be reliable (Pang et al., 2014). It can be performed on an
outpatient basis and this imaging technique takes about 5–10 min only. It
does not require special preparation other than the patient starving for
2–3 h prior to the procedure (Wilder and Patel, 2014; Armstrong et al.,
2013). Studies involving the TE in patients with chronic hepatitis B, C
viral infections and non-alcoholic fatty liver disease have shown that TE
could be superior in assessing liver fibrosis than the aspartate
aminotransferase-to-platelet ratio index (APRI) score although it is notly 2020
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
E. Sinkala et al. Heliyon 6 (2020) e04534yet validated to replace liver biopsy (Myers et al., 2010; Liu et al., 2011).
TE has been useful as a non-invasive tool in assessing liver fibrosis and
cirrhosis in HBV and HCV infected patients. It is also useful in predicting
variceal bleeding in patients with portal hypertension (Myers et al., 2010;
Jung and Kim, 2012).
The use of TE in schistosomal liver disease remains unexplored
especially in an African setting where it is quite common. It is not clear
whether HSS is associated with increased liver stiffness considering that
HSS is generally associated with periportal fibrosis and the liver paren-
chyma is spared (Sinkala et al., 2016; Rebouças, 1975). Furthermore, it is
unknown if TE can be used to discriminate between cirrhosis and HSS
and if it can be used to monitor disease progression in HSS. A study in
Egypt by Esmat et al. showed that TE overestimated the degree of liver
fibrosis in schistosomal liver disease patients who were co-infected with
HCV (Esmat et al., 2013). However, this study did not assess the per-
formance of TE in HSS patients who were mono-infected with schisto-
somiasis. We therefore aimed to evaluate liver stiffness in HSS patients
seen at the University Teaching Hospital, Lusaka, Zambia.
2. Materials and methods
2.1. Ethics statement
Informed consent was obtained from all patients and controls. Our
study was approved by the University of Zambia Biomedical Research
Ethics Committee (ref: 006-07-12).
2.2. Study settings and patient recruitment
A nested case control study was carried out at the University Teaching
Hospital in the Department of Internal Medicine between January 2015
and January 2016. During the rifaximin clinical trial of bacterial trans-
location in patients with HSS, FibroScan® became available in Lusaka,
Zambia. After amending the trial protocol, 48 sequential patients with
HSS among the patients in the rifaximin clinical trial were recruited. The
rifaximin clinical trial was a randomized clinical trial in Zambia under-
taken to test the hypothesis that rifaximin could reduce bacterial trans-
location in patients with HSS (Sinkala et al., 2018). Eighty-five (85)
patients were eligible and randomized to either rifaximin with standard
care or standard care only. Forty-four (44) patients received rifaximin
and standard care while 41 received standard care only for 42 days
(Sinkala et al., 2018). The standard care included propranolol which is a
beta blocker and was taken orally. All the patients received praziquantel
40 mg per kg body weight orally in divided doses over a day.
In this nested case control study 22 controls alongside the trial were
recruited. The controls were adults who were apparently healthy-looking
individuals and sought treatment for non-specific abdominal pains. They
were sero-negative for HIV and hepatitis B or C viruses. They had normal
gastroscopy.
The inclusion criteria for cases were: haematemesis, varices on
endoscopy, positive serology for schistosomiasis, ultrasound suggestive
of periportal fibrosis and those aged 18 years. Exclusion criteria were:
sero-positive for HIV and hepatitis B or C viruses, cirrhosis, pregnancy
and inability to give consent. The case definition for HSS in this study was
evidence of periportal fibrosis on ultrasound, positive serology for
schistosomiasis supported by presence of varices on gastroscopy.
2.3. Study procedures
A questionnaire was administered to capture demographic data,
medical history and social history. Patients and controls also underwent a
thorough physical examination. Blood from cases and controls was
drawn for full blood count (Sysmex 800i analyser, Koke, Japan). In HSS
patients, the inflammatory markers measured were tumor necrosis factor
receptor 1 (TNFR1) and soluble cluster of differentiation 14 (sCD14).
TNFR1 was measured in plasma using ELISA (R&D Systems), Abingdon,2
UK, at 10-fold dilution while soluble cluster of differentiation 14 (sCD14)
was measured by ELISA (R&D Systems) Abingdon, UK and was diluted
400-fold. Hyaluronan was measured as a marker of fibrosis using ELISA
(R&D Systems) Abingdon, UK with a dilution factor of 80. The serology
for schistosomiasis was performed using the microwell ELISA (SCI-MEDX
Corporation, Denville, NJ, USA). This gives a qualitative determination
of the immunoglobulins (IgG) to schistosoma species but does not
differentiate between species (Sinkala et al., 2016).
TE (FibroScan® 402, Echosens, Paris, France) was carried out on 48
patients with schistosomiasis related portal hypertension and 22 con-
trols. The transducer tip was placed on the lateral aspect of the liver on
the right lobe. Ten measurements were taken on each patient and each
control. Liver stiffness was taken to be valid if the success rate of valid
measurement of liver stiffness was at least 60% and the medianwas taken
as the representative measurement expressed in kiloPascals (kPa)
(Mueller and Sandrin, 2010; Kircheis et al., 2012). One of the two op-
erators of the FibroScan at the University Teaching Hospital with >1000
prior scan experience performed the scans.
2.4. Data analysis
Data analysis was carried out using STATA version 13.1 (Stata Corp,
College Station, TX, USA) and GRAPHPAD PRISM 6.01 (GraphPad Soft-
ware, San Diego, CA, USA). For data description, median with inter-
quartile range was used. Mann-Whitney test was used to compare data
between cases and controls. Spearman's rank test was used to check for
association between liver stiffness and blood markers (inflammatory and
fibrotic markers). A P value of less than 0.05 was considered significant.
3. Results
Of the 85 HSS patients in the rifaximin clinical trial (Sinkala et al.,
2018), all the 48 patients who were evaluated underwent TE. Patients
with HSS gave history of repeated exposure to natural water bodies
through swimming, drawing water for domestic use, farming and
swimming. Most of them reported exposure to water bodies during
childhood. Liver ultrasound confirmed periportal fibrosis in all the pa-
tients while the controls had no evidence of periportal fibrosis. The
controls had normal gastroscopy and gave no history of hematemesis or
rectal bleeding. Liver ultrasound did not show any evidence of cirrhosis
in cases and controls. Serum alanine aminotransferase levels in cases and
controls were not significantly different but albumin levels were lower in
the cases (Table 1). The renal function assessed by blood creatinine was
normal and comparable in cases and controls (Table 1).
The body mass index (BMI) was similar in cases and controls. None of
the cases and the controls were obese. The median age for controls was
lower than in the cases (Table 1). The female to male ratio was similar in
cases and controls (Table 1). Splenic size and main portal vein diameter
were higher in cases than controls. Nine (9) cases with HSS had ascites.
The full blood count showed that white cell count, red blood cell count
and platelet count were reduced in cases compared to controls. This may
be attributed to hypersplenism (Table 1). The stiffness of the liver was
more pronounced in cases than controls (Figure 1). We noted a signifi-
cant positive linear correlation of hyaluronan with TE. TNFR1 and TE
showed positive linear correlation as well in HSS patients (Figures 2 and
3). However, there were no significant correlations between TE scores
and other parameters.
4. Discussion
In this study, we measured liver stiffness in a well-characterized
group of Zambians with advanced HSS and noted elevated liver stiff-
ness compared with controls. This shows that TE could be an important
non-invasive method of assessing liver stiffness in HSS patients. The role
of TE in diagnosing liver disease has evolved over time such that it is now
often used in the diagnosis of cirrhosis. There is great interest in using it
Table 1. Basic demographic and laboratory data for cases and controls.
Cases (n ¼ 48) Controls (n ¼ 22) P value
Age (years) 40 (31,36) 32 (27, 35) 0.01
Gender Females 25 Females 12 1.00
Males 22 Males 10
BMI (kg/m2) 22 (21, 25) 23 (21, 26) 0.39
Spleen size (cm) 17 (15, 18) 10 (8, 11) 0.0001
Main portal vein (mm) 12 (10, 14) 8 (6, 8) 0.0001
WCC (x109/l) 2.4 (1.6, 3.4) 4.6 (3.8, 5.9) 0.0001
RBC (x1012/l) 3.4 (2.8, 4.4) 4.7 (4.4, 5.4) 0.0001
Haemoglobin (g/dl) 8 (6, 11) 14 (12, 15) 0.0001
Platelet (x109/l) 49 (27, 77) 188 (172, 295) 0.0001
ALT (U/L) 33 (17, 36) 16 (7, 30) 0.08
Albumin (g/dl) 37 (35,41) 43 (42,45) 0.001
Creatinine μmol/l 72 (64, 84) 75 (75, 88) 0.3
All parameters are represented as median and interquartile range in the parenthesis.
Key: BMI – body mass index, ALT- Alanine aminotransferase, WCC- white cell count, RBC- red blood cell count.
Figure 1. Transient elastography (FibroScan) was significantly pronounced in
cases compared to controls.
E. Sinkala et al. Heliyon 6 (2020) e04534instead of performing liver biopsy. Liver biopsy is an invasive procedure
which is associated with the risk of bleeding, injury to surrounding
structures and introduction of infection although mortality risk is as low
as 0.03% (Seeff et al., 2010). Many studies of TE have been published in
cirrhosis worldwide but to our knowledge this is the first in HSS related
portal hypertension in an African setting where schistosomiasis is very
common. A recent study was published in Brazil, which also showed that
TE is elevated in HSS but this study did not evaluate the blood markers of
inflammation and fibrosis in HSS patients (Veiga et al., 2017). When
compared with the range of reported TE scores in cirrhosis worldwide
(G€obel et al., 2015; Kircheis et al., 2012), the median TE scores seen in
our HSS patients are lower. These data suggest that TE may be a useful
tool to discriminate cirrhosis from HSS especially in HSS endemic areas.
HSS is generally characterised by normal liver cell function and the
main pathology in these patients is periportal fibrosis (Rebouças, 1975;
Da Silva et al., 2005; Sinkala et al., 2016). However, we have docu-
mented increased direct markers of fibrosis and inflammation. These
data showed positive correlation of these markers with liver stiffnessFigure 2. There was a positive correlation of FibroScan score and serum hya-
luronan, a fibrotic marker in HSS patients.
3
suggesting that hepatic parenchyma may be affected to some degree and
inflammation could be driving fibrosis in HSS. Another study in animal
models found that TNFR1 is a pro-fibrotic inflammatory marker in liver
disease (Tarrats et al., 2011). We recently reported that hyaluronan and
laminin may be important markers associated with fibrosis in HSS and
that fibrosis may be driven by systemic inflammation in HSS patients
(Sinkala et al., 2016). These findings therefore suggest that a combina-
tion of non-invasive blood markers and imaging tools such as TE may be
useful in assessing and diagnosing HSS.
Although TE seems to be good in assessing hepatic fibrosis, it has its
shortcomings. The scores tend to be influenced by obesity, acute hepa-
titis, cholestasis and performer experience (Chang et al., 2016). In this
nested case control study, no patient had obesity and there was no evi-
dence of acute hepatitis. TE was performed by an experienced person
who had performed over a thousand scans. Therefore, the TE scores
noted in our patients with HSSmay reflect the actual stiffness of the liver.
In our experience, substantial ascites results in failure to measure liver
stiffness with FibroScan. The 9 HSS patients that we included in the
analysis had trace or limited ascites detected on ultrasound and this did
not result in failure of liver stiffness measurements using FibroScan. We
suspect this minimal ascites might have increased the TE scores. We think
the presence of ascites reflected the advanced disease in HSS.
This study had some limitations. Liver biopsies were not done and
there were no cirrhotic patients as positive controls. We did not use the
Niamey protocol score to determine the image pattern for HSS patients
and therefore we acknowledge this as a limitation of the study. AnotherFigure 3. There was a positive correlation of FibroScan score and serum TNFR
1, an inflammatory marker in HSS patients.
E. Sinkala et al. Heliyon 6 (2020) e04534limitation was that we were not able to compare inflammatory markers
in chronic patients with schistosomiasis without hepatosplenic disease
and those with hepatosplenic disease. The small sample size did not allow
us to perform adjusted analyses.
In conclusion, the elevated TE scores suggest that HSS patients despite
the liver parenchyma being normal have increased liver stiffness. The
positive and significant correlations of the liver stiffness with markers of
fibrosis and inflammation support the view that inflammation may be a
driver of fibrosis leading to liver stiffness in HSS patients. The positive
correlations also suggest that HSS may have both periportal and paren-
chymal pathophysiology. A combination of non-invasive serum markers
of fibrosis and inflammation together with imaging such as TE could be of
value in clinical evaluation of HSS patients.
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